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Bayesian networksMany medical conditions are only indirectly observed through symptoms and tests. Developing predic-
tive models for such conditions is challenging since they can be thought of as ‘latent’ variables. They
are not present in the data and often get confused with measurements. As a result, building a model that
ﬁts data well is not the same as making a prediction that is useful for decision makers. In this paper, we
present a methodology for developing Bayesian network (BN) models that predict and reason with latent
variables, using a combination of expert knowledge and available data. The method is illustrated by a
case study into the prediction of acute traumatic coagulopathy (ATC), a disorder of blood clotting that sig-
niﬁcantly increases the risk of death following traumatic injuries. There are several measurements for
ATC and previous models have predicted one of these measurements instead of the state of ATC itself.
Our case study illustrates the advantages of models that distinguish between an underlying latent con-
dition and its measurements, and of a continuing dialogue between the modeller and the domain experts
as the model is developed using knowledge as well as data.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Purely data-driven approaches are currently accepted as the
primary, if not the only, way of developing predictive models.
Because of the impressive results achieved with such approaches
by organizations like Amazon and Google, it is often assumed that
this success is repeatable in other domains as long as a large
enough amount of data is available. However, a purely data-driven
approach can only predict the type of values recorded in a dataset,
such as measurements made, decisions taken or outcomes re-
corded. Even when large volumes of data exist, purely data driven
machine learning methods may not provide either accurate predic-
tions or the insights required for improved decision-making. In this
paper, we consider the common real-world situation in which suc-
cessful decision making depends on inferring underlying or latent
information that is not – and can never be – part of the data. In
such a situation a predictive model for decision support will
contain latent variables representing this underlying state but
the values of these variables will not be present in the data. We
therefore need to depend on domain expertise to identify the
important latent variables and to model relations between them
and the observed variables.Domain experts do not just substitute guesswork for data. They
may have access to information that is not machine-readable and
they should back up any judgements by reference to published re-
search whenever possible. Yet, such expert knowledge is usually
avoided in data-driven approaches using arguments such as ‘avoid-
ing subjectivity’ and ‘using facts based on the data’ [1,2]. The use of
latent variables is also limited: some data-driven approaches, such
as regression modelling, do not include latent variables at all. Other
approaches contain latent variables but these are estimated only
from data values, so that the use of latent variables in these meth-
ods does not escape the limits of the data. The objectivity of data-
driven approaches holds only so far as the prediction of observed
values really serves the needs of users. When this is not the case,
erroneous results may follow. In this paper, we show some exam-
ples of these errors and how they are avoided by appropriate and
rigorous use of domain knowledge.
We propose a pragmatic methodology to develop Bayesian
network (BN) models with latent variables. Our method integrates
domain expertise with the available data to develop and reﬁne the
model systematically through a series of expert reviews. We illus-
trate the application and results of this method with a clinical case
study of a problem for which purely data-driven approaches have
been tried but have not been considered to be successful by
clinicians. Our case study shows some possible reasons for these
past failures. It is beyond of the scope of the paper to provide full
details of the developed model, but the details can be found at
the ATC BN website [3].
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overview of our methodology. The case study is introduced in Sec-
tion 3 and developed further in Sections 4 (learning and review)
and 5 (model reﬁnement). We present our conclusion in Section 6.2. Method overview
The limitations of data for making predictions useful to a deci-
sion-maker can be summarised in three points:
1. Measurement errors: a dataset contains measurements of
variables, but measurement errors mean that the true state
of each variable differs from the measured data. In some
domains, including clinical diagnosis, this introduces sig-
niﬁcant uncertainty about the true value, so that a data-dri-
ven model cannot accurately predict the underlying state
even if it can accurately predict the associated measure-
ment values.
2. Sub-optimal decisions: the objective of a decision-support
model is to enable a decision-maker to determine the opti-
mal decisions given the observed situation. A dataset may
contain a ‘decision’ variable, that is, one that reﬂects the
decision made (e.g. a treatment given by a clinician). A
model that predicts the value of a decision variable can
be useful if all the past decision-makers had similar utilities
and they were completely rational in evaluating utilities
with their underlying uncertainties. However, there is usu-
ally no information about the utilities involved in past deci-
sions, and the data may have records of some decisions that
were incorrect at the time or, although correct at the time,
were made on outdated understanding. A model that pre-
dicts the value of a decision variable is therefore limited
in its performance even if the prediction is highly accurate.
Moreover, a model can only be used for ‘what if’ analysis –
exploring the consequences of decision alternatives – if it is
causal; choosing one of the decision alternatives erases the
factors that inﬂuenced past decisions [4]. Although these
problems are well known, models that are developed to
ﬁt past decisions are common in scientiﬁc literature (see
Section 3.1).
3. Causes of outcomes: an ‘outcome’ variable records what
happened. But outcomes can have many causes, only some
of which may be recorded in the dataset (for example, in
medical applications not all interventions and treatments
are recorded). A prediction based on only some causes
may be useful – the missing causes simply add uncertainty
– but understanding of the scope of the causes included is
important to the correct application of the model. A purely
data-driven approach does not resolve this problem; only
an expert can detect if the data omits known causes of
the outcome. If omitted causes can be identiﬁed, this infor-
mation can be used either to improve the model or to clar-
ify its scope and to assess its performance within the scope
of the causes modelled.
The main aim of our method (illustrated in the ﬂow diagram in
Fig. 1) is to overcome these limitations. We show how to develop
BNs that predict and reason with latent variables using a training
dataset including measurements of these variables, but not includ-
ing their true state. Domain expertise is used both at the start of
the development to discover latent variables and then later to
reﬁne the model in a series of expert reviews; it is during these
reviews that discrepancies between knowledge and data are re-
vealed. Expert knowledge can be used in various degrees when
deriving the structure of a BN [5]. In our method, the structure ofthe BN is developed with domain experts by using small BN frag-
ments for commonly occurring reasoning types as building-blocks
to form the complete BN structure [6]. The advantage of experts
deriving the model’s structure, rather than learning it from data,
is to ensure causal coherence: latent variables inﬂuence measure-
ments and decision variables inﬂuence outcomes. Hybrid ap-
proaches that combine expert knowledge and data can also be
used at this stage for deriving the BN structure [7,8]. Moreover,
structure learning methods can be used as a complementary ap-
proach to evaluate and reﬁne a BN structure developed by experts
[9]. Of course, all causal assumptions need to be supported by the
best available evidence, such as experimental results or expert
consensus. Lack of knowledge of true causal relationship is a prob-
lem and affects both expert and data-led modelling (aside from the
limited capabilities of algorithms such as inductive causation (IC)
[10]) alike. Equally, not all causal relationships are uncertain: it
is clear that an object’s temperature causes the thermometer read-
ing rather than the other way around.
The next step is to label the latent variables in the training data-
set, overcoming the problem that their values are unknown. The
ﬁrst label is derived from measurement data using deterministic
(but not necessarily complete) rules deﬁned by domain experts;
the second uses data clustering. The experts’ rules can be of any
form, but are typically derived from current practice. For example,
if the related measurements are continuous, these rules are thresh-
old values for the measurements. For clustering, we use the
standard Expectation–Maximisation (EM) for BNs with known
structure [11]. EM is an iterative algorithm that is used for learning
the parameters of a BN from a dataset with missing values. Each
iteration of EM has two steps: the E-step completes the data by cal-
culating the expected values of unobservable variables based on
the current set of parameters; the M-step learns a new set of
parameters from the maximum likelihood estimate of this com-
pleted data. When EM is used for parameter learning, the M-step
of the ﬁnal iteration calculates the BN parameters. When it is used
for clustering, the unobserved variables are labelled according to
the values in the E-step of the ﬁnal iteration. In our method, all
of the values of the unobserved variable are missing from the data-
set and we are using EM for clustering the unobserved values.
Although EM can also be used for structure learning [12,13] this
is not required in our method as the BN structure is developed with
domain experts. Extensions of EM that builds upon the information
bottleneck [14], variational Bayesian [15] and hierarchical [16]
frameworks have been proposed for learning latent variables.
Van der Gaag et al. [17] presents a similar approach to labelling
with expert rules where they represent combinations of multiple
observations with latent variables.
We now have two labels for each latent variable: one from clin-
ical measurements and the experts’ rules, the other from EM clus-
tering. A ﬁnal label is achieved by combining the two labels in
cases where the labels are the same and by expert review of cases
where there is a difference between the two labelling methods. We
prepare a list of cases where the labels differ. Domain experts then
decide the ﬁnal label for each data record in this list. The experts
can review other data including information that is not machine-
readable and cite relevant research to support this decision. We
also include a random subset of cases that were labelled consis-
tently in the review to assess the experts’ consistency with the
labelling by measurements and clustering approaches. This combi-
nation of expert review and data has a number of advantages. It
allows for the possibility of errors in measurement, and it uses
the experts efﬁciently. Expert review is a costly resource and using
it for every single case in the data is usually not feasible, especially
if the dataset is large. Therefore, our method aims to use it only for
ambiguous cases, where the labels from measurements conﬂict
with the results of the clustering on our data.
(2A) Clustering 
by EM
(2B) Expert Rules 
for Measurements
of Differing Cases









(1) Define BN 
Structure
(3) Expert Labelling 
Fig. 1. Method for learning BN with latent variables.
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latent variable labels have been added, to learn the BN’s parame-
ters and to evaluate its performance. We again use the EM algo-
rithm but this time to learn the parameters, since the dataset
may still contain missing values of other variables for some
patients. The second use of the EM algorithm in this step should
not be confused with the previous use of the same EM algorithm
to label latent variables in the step 2A (see Fig. 1). Expert con-
straints [18], in the form of parameter orders, can also be used if
the available data is too small for learning a part of the parameters.
We use k-fold cross-validation to evaluate the performance of the
BN. In this approach, the data is divided into k equal sized groups.
One of the k groups is used as test data while the remaining k  1
groups are used for training the BN. The learning and testingcontinues iteratively until the model is validated with all of the k
groups.
The inaccurate predictions of a predictive model offer useful
lessons for improving the model and are the focus of the next stage
of review. The BNmodelling approach is well-suited for this kind of
review since it concretely represents separate medical pathways
leading to its predictions [19,20]. When the BN model’s prediction
in the cross-validation differs from the value recorded in the data,
the domain experts investigate the reasons for this difference to
look for potential improvements to the model or clarify its scope.
The domain experts look at cases where the recorded values are
what is expected in their experience even though it is different
to what was predicted by the model. In some cases, the domain
experts may agree with the prediction of the model, and they
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as an unexpected outcome. For example, in a medical decision-
support scenario, survival of a patient with a severe injury burden
and high blood loss might be considered to be an unexpected out-
come. The expert review can also clarify scope of the model: if the
recorded outcome is explained by factors that have been excluded
from the model then this should be made clear to the model’s
users. For example, the experts might note that patient who unex-
pectedly survived did so as a result of a particular pre-hospital
treatment, and the model could not identify this as pre-hospital
interventions were out of the scope of the model. Alternatively,
additional latent variables and relations that are important for
the predictions can be discovered and added to the model. Since
the BN’s structure represents domain knowledge, any modiﬁca-
tions must be supported by evidence.
Differences between the available data and the target subpopu-
lation of the BN must be examined as the knowledge from these
two sources is combined in our method. Correlations, caused by
these differences, must be analysed and modelled in the BN struc-
ture in order to avoid developing erroneous models [21].3. Case study: trauma care
We illustrate our method with a clinical case study on acute
traumatic coagulopathy (ATC), a pathophysiological disorder
affecting the body’s ability to form a stable blood clot that occurs
following traumatic injuries and worsens outcome. The case study
was done in collaboration with Royal London Hospital (RLH), a
world leader in trauma care. A group of domain experts, including
the second and fourth authors, and a large hospital dataset were
used to develop the model with our methodology.3.1. Data-driven models in trauma care
A common approach used for data-driven predictive models,
especially in medicine, is multivariate logistic regression. These
models are functions from several predictor variables and a single
outcome variable. The regression function is estimated from a
dataset of these variables. Variables that are considered to be re-
lated with the outcome should be selected as candidate predictors.
Afterwards, a series of statistical tests are often applied to deter-
mine the least predictive candidates and remove them from the
model [22]. If the aim of the model is to make predictions, the
number and identity of the included variables are not considered
to be important [23].
Several data-driven prediction models have been developed for
decision support in trauma care but with little impact in clinical
practice due to the limitations discussed in Section 2:
1. Measurement errors: in the previous models to predict ATC,
the presence of ATC is identiﬁed with a threshold value on a
blood test called international normalised ratio (INR) [24]
despite the fact that this test has known limitations at iden-
tifying this condition. This approach has been criticised as it
fails to produce useful clinical results [25].
2. Sub-optimal decisions: models that predict the decision val-
ues in data have been developed in other areas of trauma
care. One example is decision support for injured extremi-
ties which encompasses knowledge of the presence of ATC.
Several data-driven models have been developed to predict
amputation decisions in this domain [26–28]. Although
some of these models have been used as research or evalu-
ation tools, none of them have been recommended as a
decision support tool in clinical practice [28]. The output
of these models shows the percentage of clinicians thatmade amputation decision in similar circumstances. How-
ever, recommending an amputation without relating it
with patient outcomes makes it difﬁcult to assess the
model or to understand its reasoning. Moreover, recent
advances in trauma care may have made some of the deci-
sions in the training data inappropriate for current use. A
more useful prediction for the decision-maker would be
to compare the function expected from a salvaged versus
an amputated extremity, given the characteristics of the
injury factors.
3. Causes of outcomes: permanent nerve dysfunction may be
an indication for amputation since an extremity cannot
function without nerve supply. The state of the nerve func-
tion during hospital care is available in many clinical data-
sets, and this variable has been considered as an important
factor for amputation in data-driven models [26,27]. How-
ever, nerve dysfunction has several causes, some of which
can recover [29]. Since data on nerve recovery and causes
of nerve dysfunction were not available, these factors were
ignored in the data-driven models. Considering the irre-
versible outcomes of amputation decisions, all relevant fac-
tors should be examined.
3.2. Acute traumatic coagulopathy
Up to a quarter of trauma patients develop an acute traumatic
coagulopathy (ATC) soon after their injury. These patients have a
considerably higher risk of bleeding and death since the body’s
protective mechanisms to limit bleeding are deranged. Several
effective treatment options are available if ATC can be identiﬁed
early. Immediate treatment is most effective however; standard
laboratory tests to identify ATC take over an hour to produce re-
sults. The primary aim of the BN model is therefore to predict
ATC with the information normally available within the ﬁrst
10 min of care. The methodology we have described is relevant
to this problem: the values of both ATC and of its causal factors
are measured but none of the measurements are perfectly
accurate.
3.3. ATC bayesian network structure
The initial structure of the BN, shown in Fig. 2, was developed
with domain experts using the AgenaRisk software [30]. The BN
structure contains two latent variables: ATC and Hypoperfusion.
In addition, several other variables are available in the training
dataset but are usually unobserved in the ﬁrst 10 min of treatment
when the model is designed to be used. Each of these unobserved
and latent variables is modelled with their measurements as naïve
BN fragments or ‘measurement idioms’ [6]. These naïve BN frag-
ments were used as building blocks to form the BN structure, con-
nected using causal relations elicited from experts. Table 1 shows
the variables modelled with measurement idioms. A detailed
description of the model can be found in the ATC BN website [3].
The model is divided into four components, corresponding to
the four boxes shown in Fig. 2. The remainder of this section ex-
plains the variables and relations in each of these components
brieﬂy:
 Coagulopathy: The ATC variable has two states: ‘Present’
and ‘Absent’, and it can be estimated from 5 measurements
with continuous values. None of these measurements are
available within the ﬁrst 10 min but the variables are useful
for model development. The main drivers of ATC are the
degree of tissue injury and hypoperfusion. This may be
aggravated by the infusion of large volumes of ﬂuid
(PreHosp).
Fig. 2. ATC BN structure.
Table 1
Measurement idioms in the ATC BN.
Measurements/markers
Latent variables
ATC ROTEMA5a, ROTEMA30a, INRa, PTRa, APTTRa
Hypoperfusion Lactate, BEa, pH, SBPa, HRa
Variables unobserved at ﬁrst 10 min
Chest Injury Haemothorax (HT)
Abdomen Injury FASTa Scan
Pelvic Injury Long Bone Injury (LB), Unstable Pelvis (UP)
Head Injury Glasgow Coma Score (GCS)
a APTTR: Active partial thromboplastin time ratio, BE: Base excess, FAST: Focused assessment with sonography for trauma, HR: Heart rate, INR: International normalised
ratio, PTR: Prothrombin time ratio, ROTEMA5 and A30: Amplitude of rotational thromboelastometry extem test at 5th and 30th minute, SBP: Systolic blood pressure.
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oxygen delivery to tissues as a result of blood loss, and it has
three states: ‘None’, ‘Compensated’ and ‘Uncompensated’.
 Injury: The degree of overall tissue injury may not be
known at the early stages of care. Overall tissue injury is
estimated from the mechanism and energy of injury, and
the number of severely injured body regions in the BN.
 Death: The model predicts death caused by physiological
derangements. Age is an established independent predictor
of death and has important effects on the physiological
response to injury.
A dataset of 600 trauma patients from RLH was used to learn
the parameters of this BN. In addition to latent variables ‘ATC’
and ‘Hypoperfusion’, 3% of the values are missing in the RLH data,
mainly due to recording errors or missing laboratory tests. Infer-
ence on continuous variables was calculated by the dynamic dis-
cretisation algorithm in AgenaRisk [30].
3.4. Issues with ATC measurements
The true state of ATC, which is the main outcome of our model
and a crucial factor in trauma care, cannot be directly observed in
practice, even after all the laboratory measurements have beencompleted. The ATC state is estimated using laboratory measure-
ments such as the clotting time of a blood sample. However, none
of these measurements can estimate the underlying ATC state with
complete certainty. One measurement is the INR which is the nor-
malised ratio of the clotting time of a patient’s blood plasma to the
clotting time of a healthy person. INR, and its clinically inter-
changeable measure prothrombin ratio (PTR), are the clinically
accepted standard for diagnosing ATC [31]. A normal INR value is
1, meaning that a patient has the same clotting time as a healthy
person, and higher INR values indicate coagulation problems. How-
ever, there is not a clear borderline to distinguish normal coagula-
tion from coagulopathy. Given that the actual mechanism of
coagulation is complex and incompletely understood, INR and sim-
ilar measurements have limitations that lead to uncertainty in the
diagnosis of coagulopathy:
1. INR only tests blood plasma, disregarding other components
essential to clotting such as the contribution made by platelets
and the blood vessel wall.
2. INR does not measure the strength of a formed clot, the primary
abnormality in ATC. It only measures the time it takes to form a
clot.
3. INR is designed to monitor the effects of the drug Warfarin; it is
not speciﬁcally designed for trauma.
Table 2
Criteria for labelling ATC and hypoperfusion from measurements in data.
ATC
No Yes
INR 6 1.2 INR > 1.2
Hypoperfusion
None Compensated Uncompensated
BEP 2 & Lactate 6 2 & SI < 0.9 SBP < 90 & BT > 4 BE < 4 & Lactate > 4 & BT > 0
Alive & BT in 12 h= 0 4 6 BE < 2 & 2 < Lactate 6 4 & BT > 0 Pre-hospital cardiac arrest
Died in > 48 h & BT = 0 Death from haemorrhage
BT = Blood Transfusion in 12 h, SI = Shock Index, BE = Base excess, SBP = Systolic blood pressure.
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convenient, but predicting INR is quite different from predicting
the underlying coagulopathy state. For example, Mitra et al. [24]
used an INR of 1.5 as a threshold value for classifying ATC. How-
ever, a patient with an INR of 1.3 may have serious coagulation
problems.
Consequently, the true underlying coagulopathic state of some
patients cannot be known with certainty until a completely accu-
rate way of measuring coagulopathy is discovered. Until then, cli-
nicians will continue to estimate coagulopathy using their clinical
judgement together with available measurements and observa-
tions. These clinical judgements are not recorded in the hospital
database. Only the data about INR and similar measurements are
recorded in the dataset. The situation is similar for ‘Hypoperfusion’
which is the other latent variable in our model.1 Please see Fenton and Neil [35] Chapters 1 and 10 for a discussion of the
limitations of conﬁdence intervals and test of signiﬁcance in this context.4. Learning and review
4.1. Initial labelling by expert thresholds and clustering
The latent variables were labelled twice using two different
methods: ﬁrst using measurement thresholds that reﬂect current
clinical understanding [31–33], and then by clustering using the
EM algorithm (step 2A and 2B of Fig. 1). The thresholds used for
labelling the ATC and Hypoperfusion variables are shown in
Table 2. As a result of missing data, a number of patients could
not be labelled. The labelling criteria for Hypoperfusion (see
Table 2) are not complete so this state could not be labelled for sev-
eral patients. Clustering was performed using the EM algorithm on
the BN structure shown in Fig. 2. EM uses all of the observed values
and the BN structure to classify the data into coherent groups
based on the maximum likelihood estimate of the latent variables.
We used EM to classify the data into two coherent ATC states and
three coherent hypoperfusion states.
4.2. Expert review of the labelling differences
We compared the labels given by the measurement threshold
and clustering approaches and prepared a list of the patients with
differing labels, no label and a random subset of other cases. Three
domain experts independently reviewed these cases and provided
an expert label. All clinical information was available to the experts
to assist labelling. The experts were blind to the labels assigned by
the measurement threshold and EM clustering methods. The con-
sensus between the experts’ labels was assigned as the ﬁnal label.
Table 3 shows the number of cases reviewed for the two latent
variables.
This method required the domain experts to review 188 (31%)
and 54 (9%) of the 600 cases respectively to label the hypoperfu-
sion and ATC categories. Tables 4 and 5 show the number of mea-
surement threshold labels changed after the review: for exampleTable 4 shows that 6 patients classiﬁed as coagulopathic on the ba-
sis of the INR threshold were re-classiﬁed to non-coagulopathic by
the expert review. At the end of this step, each latent variable had a
single set of labels that were obtained from the combination of
measurement threshold and clustering approaches, and the expert
review of the differing labels.4.3. Learning and cross-validation
The result of the expert review (step 3 of Fig. 1) is a dataset now
including values for the latent variables for almost all patients. The
ATC value of 4 patients and Hypoperfusion value of 5 patients re-
mained unlabelled after the expert review because the expert
was not conﬁdent about the correct value. We used the standard
EM algorithm to learn the parameters of the model. The perfor-
mance of the model trained on the RLH data was tested by 10-fold
cross validation. Only the variables that can be observed in the ﬁrst
10 min of treatment are instantiated for generating the predictions
in 10-fold cross validation.
Performance of a model can be measured in terms of its dis-
crimination, calibration and accuracy. Discrimination measures
whether the model can distinguish the patients with the event. A
model that has well discriminatory performance gives higher prob-
abilities to the patients with the event, and lower probabilities to
the patients without the event. Calibration measures whether the
predicted probability represents the correct probability on average.
For example, when a model predicts 10% chance of survival for a
group of patients, 10% of these patients are expected to survive if
the model is well calibrated. Accuracy measures whether the pre-
dicted outcomes are close to the actual outcomes by combining
features of discrimination and calibration. Medlock et al. [34] rec-
ommends using multiple performance measures to quantify differ-
ent aspects of model performance.
We used multiple performance measures to assess the discrim-
ination, accuracy and calibration of the ATC BN as recommended
by the Medlock framework [34]. The discrimination of the ATC
BN was evaluated with receiver operating characteristic (ROC)
curves, sensitivity and speciﬁcity values. The area under the ROC
curve (AUROC) is 0.90 (95% conﬁdence interval (CI): 0.86–0.94)1
and 0.81 (95% CI: 0.75–0.86) for the prediction of ATC and death
respectively. Brohi [25] argues that a useful prediction model for
coagulopathy must operate with at least 90% sensitivity: the BN
achieves speciﬁcities of 71% (95% CI: 0.67–0.74) for ATC and 44%
(95% CI: 0.39–0.48) for death when operating with 90% sensitivity.
The initial performance of the model on the cross-validation dataset
can be seen in Table 6.
The accuracy of the model was evaluated with the Brier score
(BS) and Brier skill score (BSS) [36,37]. BS is the mean squared
Table 3
Number of cases reviewed by domain expert.
Hypoperfusion ATC
Label differs No label Label same Label differs No label Label same
114 57 17 27 10 17
Total: 188 Total: 54
Table 4
Measurement threshold ATC labels changed by expert.
Measurements After review
Yes No Unlabelled
ATC label review – measurements
Yes 57 6 –
No 3 524 –
Unlabelled 1 5 4
Total: 600
Table 5
Measurement threshold hypoperfusion labels changed by expert.
Measurements After review
Uncomp. Comp. None Unlabelled
Hypoperfusion label review – measurements
Uncomp. 62 9 4 –
Comp. 1 52 5 –
None 1 6 403 –








Brier score 0.06 0.09
Brier skill score 0.32 0.15
a At 0.90 sensitivity.
b At 0.80 Sensitivity.
Fig. 3. Model calibration for ATC predictions.
Table 7
Predictions and recorded outcomes.
ATC prediction Outcome in data
P ATC = Yes ATC = No
1.0P PP 0.9 0 0
0.9 > PP 0.8 1 1
0.8 > PP 0.7 5 1
0.7 > PP 0.6 15 5
0.6 > PP 0.5 7 8
0.5 > PP 0.4 7 8
0.4 > PP 0.3 1 8
0.3 > PP 0.2 7 25
0.2 > PP 0.1 6 40
0.1 > PP 0.0 12 440
Total 61 535
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The score can take values between 0 and 1; 0 indicates a perfect
model and 1 is the worst score achievable. BSS measures theimprovement of the model’s prediction relative to a reference pre-
diction which is often the average probability of the event in the
data. BSS can take values between negative inﬁnity and 1; a nega-
tive value indicates a worse prediction than the average probability
and 1 indicates a perfect model. The BN has BS of 0.06 (95% CI:
0.05–0.07) and BSS of 0.32 (95% CI: 0.21–0.43) for ATC predictions,
BS of 0.09 (95% CI: 0.07–0.11) and BSS of 0.15 (95% CI: 0.04–0.26)
for death predictions.
The calibration of the BN was assessed with the Hosmer–Lem-
eshow test [38]. This test divides the data into 10 subgroups, and
calculates a chi-square statistic comparing the observed outcomes
to the outcomes expected by the model in each subgroup. Low
p-values indicate a lack of calibration. Hosmer–Lemeshow test is
strongly inﬂuenced by the sample size. In large datasets, small dif-
ferences between the expected and observed outcomes can lead to
low p-values but the visual representation of this test provides a
concise summary of the model calibration.
The BN was well calibrated for both ATC and death predictions
with Hosmer–Lemeshow statistics of 9.7 (p = 0.29) and 6.7
(p = 0.57) respectively. Fig. 3 is a visual representation of the mod-
el’s calibration for ATC predictions. The similarity between the ex-
pected and true outcomes in each subgroup shows that the model
was well calibrated.4.4. Inaccurate predictions and unexpected clinical outcomes
After the learning and cross-validation steps, we reviewed the
inaccurate predictions of the model with the domain experts (step
5 of Fig. 1). We divided the predictions, given by cross validation of
the model, into ten bins according to the predicted probability, and
prepared a contingency table that compares the predictions of the
model to the outcome values in data for each bin as shown in
Table 7.
The negative outcomes with ATC prediction over 0.1, and the
positive outcomes with ATC prediction less than 0.1 (shown in bold
in Table 7) were considered as the possibly inaccurate predictions
since 10% of the patients were initially labelled with ATC and thus
0.1 was our prior probability. A clinician reviewed the data and
Table 8
Inaccurate predictions and expert review.
ATC
prediction
Prediction differs from the
recorded outcome
Expert agrees with the
prediction
P
0.9 > PP 0.8 1 0 (0%)
0.8 > PP 0.7 1 1 (100%)
0.7 > PP 0.6 5 5 (100%)
0.6 > PP 0.5 8 4 (50%)
0.5 > PP 0.4 8 5 (63%)
0.4 > PP 0.3 8 6 (75%)
0.3 > PP 0.2 25 8 (32%)
0.2 > PP 0.1 40 6 (15%)
0.1 > PP 0.0 12 2 (17%)
Fig. 4. Predictions with incipient coagulopathy.
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causes of each unexpected prediction:
a. Expert agrees with the prediction: The actual outcome is
unexpected, possibly requiring further clinical investigation.
Another possible explanation is incorrectly recorded data.
b. Expert expects the recorded outcome: The model was consid-
ered to be making inaccurate predictions for these cases.
The clinician decided that the outcome value in the data is
clinically expected and analysed the causes of the inaccurate
predictions. These inaccuracies could be caused by an error
in the model structure.
Table 8 gives a summary of this review: the domain experts
agreed with about a third of the apparently inaccurate predictions.
During the review, domain experts explained why they agreed
with the individual predictions or recorded outcomes which led
to a number of reﬁnements to the model and to the clinicians’
understanding of the data. Death predictions were also reviewed
by the same approach. We describe these issues and the way the
model was reﬁned in the following section.
5. Model reﬁnement
Three issues were found from the review of inaccurate
predictions:
1. ATC may develop in some patients soon after the blood test
used for INR and other measurements was taken.
2. Some of the deaths recorded in the dataset were most likely due
to conditions other than ATC.
3. There are mechanisms of coagulopathy other than ATC that may
be occurring in patients in the dataset.
These issues all challenge the supposed objectivity of data and
reinforce the need to combine data with expert review. The follow-
ing sections describe these issues in more detail.
5.1. Incipient coagulopathy
A group of patients who had normal values for their initial ATC
measurements (see Table 1) showed signiﬁcant signs of ATC in a
second set of measurements that were conducted soon after. More-
over, these patients had severe injury burden and poor perfusion;
they were therefore at high clinical risk of developing ATC. The
ATC model predicts high risk of coagulopathy for these patients
but the value in the data is negative since only the initial measure-
ments were considered while labelling the ATC state of patients
with measurement thresholds and clustering approaches.
Coagulopathy is a dynamic phenomenon that develops in time,
so the results of measurements are dependent on the time they arecarried out. Variations in the interval between the injury and the
arrival at the hospital add further uncertainty. Therefore, the do-
main experts considered the prediction of those patients with
‘incipient coagulopathy’ as a clinically useful feature of the BN.
We re-learnt the ATC BN and recalculated its performance in a
cross validation when patients with incipient ATC were also con-
sidered as positive outcomes. The structure of the ATC BN was
not changed in this analysis. Fig. 4 compares the ROC curves for
ATC prediction based on only the initial measurements with the
one for patients with incipient ATC. The AUROC is 0.92 (95% CI:
0.89–0.95), and the model achieves speciﬁcity of 79% (95% CI:
0.76–0.82) at the sensitivity 90% level, BS of 0.06 (95% CI: 0.05–
0.07) and BSS of 0.39 (95% CI: 0.27–0.50).
Prediction of incipient coagulopathy shows the difference be-
tween the clinically useful models and the models that predict
measurements in data well. The patients with incipient coagulop-
athy would count as incorrect predictions for a purely data-based
approach, and such an approach would try to change the parame-
ters to ‘correct’ these predictions. In contrast, the expert was able
to explain the apparent anomaly and show that predicting incipi-
ent coagulopathy was useful; this was not obvious at the beginning
of the model development.5.2. Other causes of death
The review revealed that a large proportion of deaths that could
not be predicted by the BN were the result of head injuries and
thus these deaths were expected by the domain experts. The ATC
model is designed to predict risk of death relevant to bleeding
and coagulopathy, so the initial model does not predict deaths
related to head injuries. However, the model structure is easily
modiﬁed to predict these deaths since we already have a head in-
jury variable in the model which is used to estimate the overall tis-
sue injury burden of patients. By adding an arc between head
injury and death variable, we increase the accuracy of the model
for death prediction. Although death might be considered to be
the least ambiguous outcome in a clinical dataset, our experience
Fig. 5. Predictions with head injury modiﬁcation.
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the modelled and actual cause of death.
This simple modiﬁcation increased the accuracy of death pre-
dictions signiﬁcantly. The AUROC increased from 0.81 (95% CI:
0.75–0.86) to 0.88 (95% CI: 0.84–0.92) as shown in Fig. 5. The spec-
iﬁcity of the BN is increased from 44% (95% CI: 0.39–0.48) to 72%
(95% CI: 0.67–0.76) when it is operated at 90% sensitivity level.
BS and BSS also indicated an increased accuracy in the death
predictions: BS of the BN decreased from 0.09 (95% CI: 0.07–0.11)
to 0.08 (95% CI: 0.06–0.10); and BSS increased from 0.15Fig. 6. BN structure reﬁned for brai(95% CI: 0.04–0.26) to 0.23 (95% CI: 0.13–0.33). This change had
no impact on ATC prediction.
5.3. Unmodelled mechanisms of coagulopathy
The aim of this BN is to predict ATC, which is driven by a com-
bination of the degree of tissue injury and hypoperfusion following
traumatic injuries. The scope of the model has to be clearly deﬁned
since other forms of coagulopathy exist. For example, the anticoag-
ulation medicine Warfarin makes a person coagulopathic without
any traumatic injury, and predicting drug induced coagulopathy
is out of scope for this model.
Another important cause of traumatic coagulopathy is a cata-
strophic brain injury. These injuries seem to effect coagulation
via a different mechanism to ATC. The review of unexpected pre-
dictions showed that 9 of the 12 coagulopathic patients that the
BN model could not accurately predict had severe head injuries,
and in 7 of these patients brain injury was fatal. It is likely that
these patients were suffering from a coagulopathy caused by brain
injury (BIC) rather than ATC.
BIC is now documented as being outside the scope of our BN.
This issue was not clear at the beginning of the model development
even though the clinicians were aware of the phenomenon; it was
identiﬁed as a result of the review of inaccurate predictions with
the domain expert. If prediction of the BIC is required by the users,
the model structure can be adapted accordingly by adding two
variables ‘BIC’ and ‘Coagulopathy’ as shown in Fig. 6. In this model
fragment, ‘Coagulopathy’ variable represents the overall coagulop-
athy risk that sums the risk of ‘BIC’ and ‘ATC’ variables.6. Conclusion
This paper proposed a method for developing and reﬁning BNs
with latent clinical conditions, using a combination of expert
knowledge and data. The method is successfully applied to a clin-
ical case study about the prediction of ATC in trauma care. Our
method addresses the problems related to measurement errors
and causes of outcomes by:n injury induced coagulopathy.
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wish to predict for decision support and any measurements of
this variable that may be recorded in a dataset; both latent
and observed variables are represented explicitly in the BN
model.
2. Using iterative expert review of the model to reﬁne the model
and to understand the relationship between the data and the
real decision problem.
Our methodology systematically integrated domain expertise
into model development at two stages. Firstly, the ‘true’ but unob-
served state was added to a dataset by combining labelling by
observed measurements with data clustering in an expert-elicited
BN structure. Focussing the detailed expert review on the cases
labelled differently in these two steps saves time compared to a
review of all cases. Secondly, the experts examined differences be-
tween the model’s predictions and the data.
In our case study, this examination revealed several issues
initially neglected by our experts and emphasised the difference
between useful predictions for the decision-maker and an accurate
prediction of measurements in data. Other latent and observed
causes of predicted outcomes, which were not clear at the begin-
ning, were modelled during the review. These issues were resolved
either by reﬁning the model or by acknowledging the scope of its
applicability, which were not obvious at the initial stages of model
development.
The case study demonstrates signiﬁcant improvements in pre-
dictions from the iterative expert reviews and reﬁnements. Identi-
fying and including the other causes of death increased the
speciﬁcity for death predictions from 44% (95% CI: 0.39–0.48) to
72% (95% CI: 0.67–0.76) when the model is operated at 90% sensi-
tivity. Similarly, identifying the clinically important patient sub-
group with incipient coagulopathy increased the speciﬁcity for
ATC predictions from 71% (95% CI: 0.67–0.74) to 79% (95% CI:
0.76–0.82) at 90% sensitivity.
As further research, we are examining practical approaches that
use domain expertise to resolve problems related to predicting
decisions. In addition, the dialogue between the expert and the
model has so far focussed exclusively on the global performance
of the model. Since the model’s structure corresponds to the ex-
pert’s understanding of the domain, we are investigating how to
compare the internal operation of the model with the clinical rea-
soning applied to a particular patient. Moreover, a graphical inter-
face that assists the expert in reviewing of inaccurate predictions
would also be useful.References
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